Cargando…

Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson’s Disease

We previously demonstrated that spare respiratory capacity of the TCA cycle enzyme alpha-ketoglutarate dehydrogenase (KGDH) was completely abolished upon increasing levels of MAO-B activity in a dopaminergic cell model system (Kumar et al., J Biol Chem 278:46432–46439, 2003). MAO-B mediated increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallajosyula, Jyothi K., Chinta, Shankar J., Rajagopalan, Subramanian, Nicholls, David G., Andersen, Julie K.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727365/ https://www.ncbi.nlm.nih.gov/pubmed/19526285 http://dx.doi.org/10.1007/s12640-009-9032-2

Ejemplares similares

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2008)

Correction: MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2012)

A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson's Disease
por: Chinta, Shankar J., et al.
Publicado: (2012)

Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson’s Disease
por: Chinta, Shankar J., et al.
Publicado: (2018)

MAO-B elevation decreases parkin's ability to efficiently clear damaged mitochondria: protective effects of rapamycin
por: Siddiqui, Almas, et al.
Publicado: (2012)

Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein–Inhibitor Complexes in Relevance to Developing Parkinson’s Therapeutics
por: Murugan, Natarajan Arul, et al.
Publicado: (2020)

Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease
por: Lieu, Christopher A., et al.
Publicado: (2013)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
por: Krishna, Rakhee, et al.
Publicado: (2014)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs
por: Hagenow, Jens, et al.
Publicado: (2020)

Maó
por: Quintana, Josep M. (Josep Maria)
Publicado: (1996)

Changes of MAO-A and MAO-B Expressions in the Placenta of MPTP or MPP(+) Treated Mice
por: Sai, Takafumi, et al.
Publicado: (2013)

Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson's Disease
por: Leonoudakis, Dmitri, et al.
Publicado: (2017)

Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
por: Cho, Hyun-U, et al.
Publicado: (2021)

Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
por: Viel, Tania, et al.
Publicado: (2020)

Mao : a biography /
por: Terrill, Ross
Publicado: (1981)

MAO-B Polymorphism Associated with Progression in a Chinese Parkinson's Disease Cohort but Not in the PPMI Cohort
por: Cui, Shi-Shuang, et al.
Publicado: (2022)

Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
por: Fowler, Joanna S, et al.
Publicado: (2015)

Mao Zedong
por: Grimm, Tilemann
Publicado: (1986)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
por: Duarte, Pablo, et al.
Publicado: (2022)

Monoamine Oxidase Inhibitory Constituents of Propolis: Kinetics and Mechanism of Inhibition of Recombinant Human MAO-A and MAO-B
por: Chaurasiya, Narayan D., et al.
Publicado: (2014)

PLATELET MAO ACTIVITY IN CHRONIC SCHIZOPHRENIA
por: Gupta, A.K., et al.
Publicado: (1985)

Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach
por: Baweja, Gurkaran Singh, et al.
Publicado: (2023)

Mao Tse-Tung
por: Payne, Robert
Publicado: (1972)

Mao Tse-tung
por: MacGregor-hastie, Roy

ADHD and Disruptive behavior scores – associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents
por: Malmberg, Kerstin, et al.
Publicado: (2008)

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease
por: Nam, Min-Ho, et al.
Publicado: (2021)

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review
por: Tsuboi, Takashi, et al.
Publicado: (2022)

Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disorder
por: Kumar, Sunil, et al.
Publicado: (2023)

Individual and Combined Effect of MAO-A/MAO-B Gene Variants and Adverse Childhood Experiences on the Severity of Major Depressive Disorder
por: Toledo-Lozano, Christian Gabriel, et al.
Publicado: (2023)

Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus
por: Minami, M., et al.
Publicado: (2006)

Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease
por: Wang, Xuebao, et al.
Publicado: (2017)

Mao Tse-Tung : un revolucionario
por: Payne, Pierre Stephen Robert, 1911-
Publicado: (1965)

Cannot write session to /tmp/vufind_sessions/sess_blin56ngl8jfrle3e48gemlmlr